Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced the appointment of six leading experts to its newly formed Strategic Advisory Board (SAB). The SAB will work with the leadership team and will advise the Company on its scientific, medical, translational and developmental strategy.
“We are proud to have a team of independent world-renowned experts in immunology and oncology joining us,” commented, Eric Vivier, Chief Scientific Officer of Innate Pharma. “Since its inception, Innate Pharma has been at the forefront of immunology to translate scientific discoveries into innovative treatments against cancer. The outstanding and highly complementary expertise of the SAB members, within this advisory committee, will provide insight to nurture the science developed at Innate Pharma by combining multidisciplinary approaches and state-of-the-art technologies.”
Pierre Dodion, Chief Medical Officer of Innate Pharma, added: “At Innate Pharma, we have always seen preclinical and clinical activities as highly interrelated activities. We are committed to continuing to focus on bringing new therapeutic options to patients suffering from cancer and actively progressing our pipeline of innovative immuno-oncology drug candidates toward later clinical stage developments. A strong scientific accent will also guide our commercial activities, which are starting with Lumoxiti. The individuals who have joined our SAB will provide robust scientific and medical guidance and provide critical support across our activities.”